LRP1 and Alzheimer disease: These changes decreased GSK-3β, ApoE4, and AD-associated proteins (APP, Aβ, p-Tau), while enhancing low-density lipoprotein receptor-related protein 1 (LRP1)-mediated Aβ clearance.